In addition, based on the results obtained in MM patients, the efficacy and safety of anti-CD38 MoAb are now being evaluated in other plasma cell dyscrasias such as smoldering MM and in immunoglobulin light-chain amyloidosis [24]. This evidence concerns the gene CD38 and AL amyloidosis.